Is PayPal Stock Finally a Buy?
Shares of online payment giant PayPal (NASDAQ:PYPL) have struggled over…
Sell
50
DRUG Quote, Financials, Valuation and Earnings
Last price:
$58.74
Seasonality move
:
-14.37%
Day range:
$55.50 - $59.30
52-week range:
$23.18 - $70.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.97x
Volume:
82.6K
Avg. volume:
130.3K
1-year change:
21.17%
Market cap:
$416.7M
Revenue:
--
EPS (TTM):
-$0.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
-- | -$1.08 | -- | -509.76% | $93.21 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NKTR
Nektar Therapeutics
|
$9.8M | -$2.59 | -63.4% | -1474.64% | $93.86 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.21 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
$58.79 | $93.21 | $416.7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.06 | $0.85 | $6.4M | 4.87x | $0.80 | 0% | 1.11x |
|
NKTR
Nektar Therapeutics
|
$55.97 | $93.86 | $968.3M | -- | $0.00 | 0% | 83.75x |
|
NNVC
NanoViricides, Inc.
|
$1.84 | $7.00 | $32.1M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$1.12 | $2.00 | $919.4K | -- | $0.00 | 0% | 0.53x |
|
TOVX
Theriva Biologics, Inc.
|
$0.28 | $7.00 | $2.7M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
0.27% | 0.909 | 0.06% | 84.94x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
19.71% | 0.638 | 30.81% | 2.56x |
|
NKTR
Nektar Therapeutics
|
115.87% | 5.372 | 55.13% | 2.46x |
|
NNVC
NanoViricides, Inc.
|
-- | -0.019 | -- | -- |
|
OGEN
Oragenics, Inc.
|
343.92% | 0.299 | 109.72% | 0.46x |
|
TOVX
Theriva Biologics, Inc.
|
21.39% | -2.753 | 73.56% | 0.98x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences, Inc.
|
-$11.4K | -$2.4M | -25.32% | -25.41% | -- | -$2.6M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
-$38K | -$1.9M | -219.31% | -364.55% | -44% | -$3M |
|
NKTR
Nektar Therapeutics
|
$11.8M | -$31.5M | -52.6% | -341.85% | -320.21% | -$45.8M |
|
NNVC
NanoViricides, Inc.
|
-- | -$2.2M | -- | -- | -- | -$2M |
|
OGEN
Oragenics, Inc.
|
-- | -$1.7M | -598.59% | -2338.9% | -- | -$1.3M |
|
TOVX
Theriva Biologics, Inc.
|
-$27K | -$4M | -136.39% | -151.61% | -- | -$4.7M |
Bright Minds Biosciences, Inc. vs. Competitors
-
Which has Higher Returns DRUG or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of -49.65%. Bright Minds Biosciences, Inc.'s return on equity of -25.41% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -364.55%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.53 $38.1M NBYNovaBay Pharmaceuticals, Inc.65.26% -$0.33 $5.3M -
What do Analysts Say About DRUG or NBY?
Bright Minds Biosciences, Inc. has a consensus price target of $93.21, signalling upside risk potential of 58.55%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that Bright Minds Biosciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Bright Minds Biosciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.5 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is DRUG or NBY More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.667%.
-
Which is a Better Dividend Stock DRUG or NBY?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NBY?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$3.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$2M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 1.11x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$3.8M NBYNovaBay Pharmaceuticals, Inc.1.11x 4.87x -- -$2M
-
Which has Higher Returns DRUG or NKTR?
Nektar Therapeutics has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of -372.2%. Bright Minds Biosciences, Inc.'s return on equity of -25.41% beat Nektar Therapeutics's return on equity of -341.85%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.53 $38.1M NKTRNektar Therapeutics98.09% -$1.87 $152.5M -
What do Analysts Say About DRUG or NKTR?
Bright Minds Biosciences, Inc. has a consensus price target of $93.21, signalling upside risk potential of 58.55%. On the other hand Nektar Therapeutics has an analysts' consensus of $93.86 which suggests that it could grow by 67.69%. Given that Nektar Therapeutics has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Nektar Therapeutics is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.5 0 0 NKTRNektar Therapeutics4 1 0 -
Is DRUG or NKTR More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.191, suggesting its more volatile than the S&P 500 by 19.109%.
-
Which is a Better Dividend Stock DRUG or NKTR?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NKTR?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. Bright Minds Biosciences, Inc.'s net income of -$3.8M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 83.75x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$3.8M NKTRNektar Therapeutics83.75x -- $11.8M -$35.5M
-
Which has Higher Returns DRUG or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -25.41% beat NanoViricides, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.53 $38.1M NNVCNanoViricides, Inc.-- -$0.14 -- -
What do Analysts Say About DRUG or NNVC?
Bright Minds Biosciences, Inc. has a consensus price target of $93.21, signalling upside risk potential of 58.55%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 253.26%. Given that NanoViricides, Inc. has higher upside potential than Bright Minds Biosciences, Inc., analysts believe NanoViricides, Inc. is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.5 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is DRUG or NNVC More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.147, suggesting its more volatile than the S&P 500 by 14.697%.
-
Which is a Better Dividend Stock DRUG or NNVC?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NNVC?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are larger than NanoViricides, Inc. quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$3.8M is lower than NanoViricides, Inc.'s net income of -$2.2M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$3.8M NNVCNanoViricides, Inc.-- -- -- -$2.2M
-
Which has Higher Returns DRUG or OGEN?
Oragenics, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -25.41% beat Oragenics, Inc.'s return on equity of -2338.9%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.53 $38.1M OGENOragenics, Inc.-- -$3.10 $872.3K -
What do Analysts Say About DRUG or OGEN?
Bright Minds Biosciences, Inc. has a consensus price target of $93.21, signalling upside risk potential of 58.55%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 79%. Given that Oragenics, Inc. has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Oragenics, Inc. is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.5 0 0 OGENOragenics, Inc.1 0 0 -
Is DRUG or OGEN More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.801, suggesting its less volatile than the S&P 500 by 19.917%.
-
Which is a Better Dividend Stock DRUG or OGEN?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or OGEN?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$3.8M is lower than Oragenics, Inc.'s net income of -$2.3M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$3.8M OGENOragenics, Inc.0.53x -- -- -$2.3M
-
Which has Higher Returns DRUG or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -25.41% beat Theriva Biologics, Inc.'s return on equity of -151.61%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences, Inc.-- -$0.53 $38.1M TOVXTheriva Biologics, Inc.-- -$1.93 $13.5M -
What do Analysts Say About DRUG or TOVX?
Bright Minds Biosciences, Inc. has a consensus price target of $93.21, signalling upside risk potential of 58.55%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2425.25%. Given that Theriva Biologics, Inc. has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences, Inc.5 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is DRUG or TOVX More Risky?
Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.540, suggesting its less volatile than the S&P 500 by 46.013%.
-
Which is a Better Dividend Stock DRUG or TOVX?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or TOVX?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$3.8M is higher than Theriva Biologics, Inc.'s net income of -$13.1M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences, Inc.-- -- -- -$3.8M TOVXTheriva Biologics, Inc.0.33x -- -- -$13.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Sprouts Stock Fall So Much?
Shares of health-oriented grocery chain Sprouts Farmers Market (NASDAQ:SFM) have…
Why Did Amazon Go Up So Much?
Shares of Amazon (NASDAQ:AMZN) soared late last week, bringing the…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 36x
Alerts
Buy
100
GMED alert for Nov 8
Globus Medical, Inc. [GMED] is up 35.94% over the past day.
Buy
73
GCT alert for Nov 8
GigaCloud Technology, Inc. [GCT] is up 30.05% over the past day.
Buy
84
FROG alert for Nov 8
JFrog Ltd. [FROG] is up 26.96% over the past day.
